Japan-based Global Health Innovative Technology Fund invests US$22 million to develop drugs for malaria, tuberculosis, Chagas disease, visceral leishmaniasis

The Global Health Innovative Technology Fund (GHIT), a Japan-based international private-public partnership, announced that it will provide ¥2.3 billion (US$22 million) to develop new drugs for malaria, tuberculosis, Chagas disease, and visceral leishmaniasis, as well as a vaccine for malaria and diagnostics for tuberculosis.

GHIT is funded by a mix of private and public funders, notably the Japanese government, the United Nations Development Programme (UNDP), the Bill & Melinda Gates Foundation, and the Wellcome Trust, along with a growing list of private sector funders and collaborators. In 2020, GHIT invested a total of ¥4.2 billion (US$40 million)

As of March 31, 2021, GHIT is funding 57 projects, comprised of 30 in their discovery stages, 20 preclinical studies, and 7 clinical trials.

Press release - Global Health Innovative Technology Fund